Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients; Public Workshop; Request for Comments

Özet

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled "Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients." The purpose of the public workshop is to discuss the scientific and clinical trial design considerations for development of antiviral products to treat adenoviral infection.